Cancer Immunology Research Journal Citation Rate 2026
2326-6066
eISSN 2326-6074
American Association for Cancer Research
US
Q2 Quartile
About Cancer Immunology Research
Cancer Immunology Research (CIR) is a peer-reviewed academic journal, published by American Association for Cancer Research in US, catalogued under ISSN 2326-6066 (e-ISSN 2326-6074). As of 2026, it has a 2025 2-Year Citation Rate (OpenAlex) of 1.77 (Q2 quartile) — the average number of citations its recent articles received over a two-year window, computed from OpenAlex open citation data, not the Clarivate (JCR) Impact Factor. It operates a subscription model.
Cancer Immunology Research Citation Rate 2026 — In Context
Cancer Immunology Research has a 2025 2-Year Citation Rate (OpenAlex) of 1.77, placing it in the Q2 quartile. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not the Clarivate (JCR) Journal Impact Factor.
Cancer Immunology Research operates a subscription-based publishing model — readers access articles through institutional subscriptions or pay-per-view.
Researchers looking to publish in Cancer Immunology Research should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Cancer Immunology Research against similar journals in the field, use our journal comparison tool.
| ISSN (Print) | 2326-6066 |
|---|---|
| ISSN (Online) | 2326-6074 |
| Publisher | American Association for Cancer Research |
| Country | United States |
| APC / Cost | Inquire with Publisher |
| h-index | 172 |
| Total Works | 5,019 |
| Total Citations | 127,971 |
| 2-yr Mean Citedness | 2.39 (OpenAlex) |
In-depth profile & metrics
Cancer Immunology Research is published by American Association for Cancer Research and based in United States.
Editorially, Cancer Immunology Research concentrates on Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses and CAR-T cell therapy research.
Cancer Immunology Research is indexed in OpenAlex. OpenAlex tracking provides an open, citable record of its output even where commercial indexing is absent.
OpenAlex records 5,019 works that have together drawn 127,971 citations, giving the journal an h-index of 172; its most recent citation rate stands at 1.765; OpenAlex puts its two-year mean citedness at 2.39.
Links
Continue on JournalsHub
Put what you just read into practice with these free tools.
Frequently Asked Questions about Cancer Immunology Research
Live Indexing Status
Updated April 2026Track real-time indexing metrics to ensure this journal meets your academic requirements.
Citation Rate
Historical Trend
Initial data points onlyCitation Rate by Year
| Year | Value | Source |
|---|---|---|
| 2025 | 1.765 | 2-Year Mean Citedness (OpenAlex) |
Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.
Works Published per Year (2014–2025)
Annual publication volume sourced from OpenAlex. Current year omitted (partial data).
Publication & citation history by year
| Year | Works published | Citations received |
|---|---|---|
| 2025 | 451 | 776 |
| 2024 | 271 | 1,719 |
| 2023 | 234 | 2,546 |
| 2022 | 363 | 4,566 |
| 2021 | 234 | 5,589 |
| 2020 | 579 | 9,832 |
| 2019 | 640 | 16,799 |
| 2018 | 308 | 13,968 |
| 2017 | 277 | 13,443 |
| 2016 | 772 | 12,949 |
| 2015 | 312 | 16,378 |
| 2014 | 138 | 18,823 |
Journal at a Glance
Source: OpenAlex — refreshed daily.
Top Research Topics
The areas where Cancer Immunology Research most frequently publishes, ranked by article volume. Click a topic to see the best journals for it.
Explore More Journals
Metadata
Last updated: Apr 24, 2026
Updated by: openalex_bulk
OpenAlex ID: S2765010658
Get weekly updates
Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.